arrow_back Back to App

New law facilitates discounted drug access for clinical trials.

This act aims to reduce the cost of drugs for researchers conducting clinical trials. This could make research into new medicines and therapies cheaper and faster, potentially leading to the availability of innovative treatments for citizens in the future. It also introduces legal mechanisms to ensure drug manufacturers comply with these rules.
Key points
Researchers can purchase drugs for clinical trials at a discounted price, equal to production costs.
Drug manufacturers must sell these products at the discounted price if the researcher meets the conditions.
If a manufacturer refuses to sell, the researcher can sue them and obtain a court order for sale and damages.
The act aims to accelerate the development of new drugs and therapies, potentially benefiting patients.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_4026
Sponsor: Sen. Smith, Tina [D-MN]
Process start date: 2022-04-07
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Discounted Drugs for Clinical Trials Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_4026.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2022-04-07.

What are the main provisions?

Key points include:

  • Researchers can purchase drugs for clinical trials at a discounted price, equal to production costs.
  • Drug manufacturers must sell these products at the discounted price if the researcher meets the conditions.
  • If a manufacturer refuses to sell, the researcher can sue them and obtain a court order for sale and damages.
  • The act aims to accelerate the development of new drugs and therapies, potentially benefiting patients.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Smith, Tina [D-MN].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health Courts and Law